Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget Ročník 7; číslo 41; s. 67314 - 67320
Hlavní autoři: Kaga, Yasuhiro, Sunakawa, Yu, Kubota, Yutaro, Tagawa, Teppei, Yamamoto, Taikan, Ikusue, Toshikazu, Uto, Yu, Miyashita, Kouichirou, Toshima, Hirokazu, Kobayashi, Kouji, Hisamatsu, Atsushi, Ichikawa, Wataru, Sekikawa, Takashi, Shimada, Ken, Sasaki, Yasutsuna
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 11.10.2016
Témata:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Prognosis
Treatment Outcome
FOLFIRINOX
pancreatic cancer
early tumor shrinkage
ISSN:1949-2553
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions' diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.
AbstractList There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions' diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.
Author Kobayashi, Kouji
Yamamoto, Taikan
Hisamatsu, Atsushi
Kubota, Yutaro
Sekikawa, Takashi
Toshima, Hirokazu
Ichikawa, Wataru
Sasaki, Yasutsuna
Tagawa, Teppei
Sunakawa, Yu
Uto, Yu
Miyashita, Kouichirou
Ikusue, Toshikazu
Shimada, Ken
Kaga, Yasuhiro
Author_xml – sequence: 1
  givenname: Yasuhiro
  surname: Kaga
  fullname: Kaga, Yasuhiro
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 2
  givenname: Yu
  surname: Sunakawa
  fullname: Sunakawa, Yu
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 3
  givenname: Yutaro
  surname: Kubota
  fullname: Kubota, Yutaro
  organization: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan
– sequence: 4
  givenname: Teppei
  surname: Tagawa
  fullname: Tagawa, Teppei
  organization: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan
– sequence: 5
  givenname: Taikan
  surname: Yamamoto
  fullname: Yamamoto, Taikan
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 6
  givenname: Toshikazu
  surname: Ikusue
  fullname: Ikusue, Toshikazu
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 7
  givenname: Yu
  surname: Uto
  fullname: Uto, Yu
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 8
  givenname: Kouichirou
  surname: Miyashita
  fullname: Miyashita, Kouichirou
  organization: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 9
  givenname: Hirokazu
  surname: Toshima
  fullname: Toshima, Hirokazu
  organization: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan
– sequence: 10
  givenname: Kouji
  surname: Kobayashi
  fullname: Kobayashi, Kouji
  organization: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan
– sequence: 11
  givenname: Atsushi
  surname: Hisamatsu
  fullname: Hisamatsu, Atsushi
  organization: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan
– sequence: 12
  givenname: Wataru
  surname: Ichikawa
  fullname: Ichikawa, Wataru
  organization: Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan
– sequence: 13
  givenname: Takashi
  surname: Sekikawa
  fullname: Sekikawa, Takashi
  organization: Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan
– sequence: 14
  givenname: Ken
  surname: Shimada
  fullname: Shimada, Ken
  organization: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan
– sequence: 15
  givenname: Yasutsuna
  surname: Sasaki
  fullname: Sasaki, Yasutsuna
  organization: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27634903$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtOwzAQRS0EoqX0A9ggL9mkOM7DzhJVLVSqqIRAYldN7EkbSOxiO0Xd8O2kPGYzmnuOZnEvyKmxBgm5itkklnnCb61RNoDbYJjEnDFxQoZxkRYRz7JkQMbev7F-slRIXpyTARd5khYsGZKvGbjmQEPXWkf91tXmHTZIwVOgO4e6VqEHtqIV7K2DskFqu6Bsi57Whu4g1GiCp5912FLQezAKdR8b5bBniqpj4mg4nj358ear5XzxtHhcvV6Sswoaj-O_PSIv89nz9CFaru4X07tlpNK8CBFoKIok1TnkBaYoklxlCkFWZSKFiEuQiFpWTAreK7oqUTItU1lhpkQsUj4iN79_d85-dOjDuq29wqYBg7bz61j2RXEhGevV6z-1K1vU652rW3CH9X9n_Bt6XXMD
CitedBy_id crossref_primary_10_3390_cancers11070939
crossref_primary_10_1016_j_pan_2025_02_005
crossref_primary_10_1186_s12876_021_01870_x
crossref_primary_10_1002_cam4_71251
crossref_primary_10_1186_s40001_024_02001_4
crossref_primary_10_1016_j_pan_2024_07_006
crossref_primary_10_1007_s00280_017_3422_6
crossref_primary_10_1038_s41598_018_37147_9
crossref_primary_10_1177_17588359231175441
crossref_primary_10_1007_s00595_020_02220_2
crossref_primary_10_3390_biomedicines12030507
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.18632/oncotarget.12007
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1949-2553
EndPage 67320
ExternalDocumentID 27634903
Genre Journal Article
GroupedDBID ---
53G
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CGR
CUY
CVF
DIK
ECM
EIF
FRJ
GX1
HYE
KQ8
M48
NPM
OK1
PGMZT
RPM
7X8
ID FETCH-LOGICAL-c469t-ada9934d6a69e4e736c5cea8fb38771ba8eed8f08726a6dfbe80d848fe5c71742
IEDL.DBID 7X8
ISICitedReferencesCount 16
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000387446200076&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
IngestDate Thu Jul 10 22:32:35 EDT 2025
Mon Jul 21 05:40:10 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 41
Keywords FOLFIRINOX
pancreatic cancer
early tumor shrinkage
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-ada9934d6a69e4e736c5cea8fb38771ba8eed8f08726a6dfbe80d848fe5c71742
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=12007&path%5B%5D=37999
PMID 27634903
PQID 1855327800
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1855327800
pubmed_primary_27634903
PublicationCentury 2000
PublicationDate 2016-10-11
PublicationDateYYYYMMDD 2016-10-11
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-11
  day: 11
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncotarget
PublicationTitleAlternate Oncotarget
PublicationYear 2016
SSID ssj0000547829
Score 2.216137
Snippet There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 67314
SubjectTerms Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Prognosis
Treatment Outcome
Title Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
URI https://www.ncbi.nlm.nih.gov/pubmed/27634903
https://www.proquest.com/docview/1855327800
Volume 7
WOSCitedRecordID wos000387446200076&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qevDiA1_riwhe67bpa3oSEYsL2l1EobeS5oGCtmvb3aO_3Unb1ZMgCCWHNKUlmX7zzYMZQi6k46sAIsfKXV9aHiAO5oJry5UK-YHgAJy3zSbCJIE0jaa9w63u0yqXmNgCtSyF8ZGPUK_4LguR31zNPizTNcpEV_sWGqtk4CKVMVIdpvDtY7FNsSoW9cFMCFw2Kk3JgzbH-tIxbrrfiWWrYOKt_37aNtnsqSW97mRhh6yoYpd8thWMaTN_Lytav1RoeiKCUF5TTmeVidKg0U1LTTVfoDTkb4qW8wbfq2r6WtC-7GpNjb-WLhMGcLro2KagwsxUtE1YxzvtunhyH48fx8kk3SPP8e3TzZ3V91ywBBrKjcUlR8biyYAHkfJU6AbCF4qDzl0IQyfngEoVtA0hwyVS5wpsCR5o5Qu0DD22T9aKslCHhCKS6CCMmPQg95QKOGeO4EozLcDHa0jOl9uZoUybQAUvVDmvs58NHZKD7kyyWVd8I2MIiF5ku0d_ePqYbCC_CYyqcZwTMtD4R6tTsi4WzWtdnbXCgmMyffgCik7Plg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+tumor+shrinkage+as+a+predictor+of+favorable+outcomes+in+patients+with+advanced+pancreatic+cancer+treated+with+FOLFIRINOX&rft.jtitle=Oncotarget&rft.au=Kaga%2C+Yasuhiro&rft.au=Sunakawa%2C+Yu&rft.au=Kubota%2C+Yutaro&rft.au=Tagawa%2C+Teppei&rft.date=2016-10-11&rft.eissn=1949-2553&rft.volume=7&rft.issue=41&rft.spage=67314&rft_id=info:doi/10.18632%2Foncotarget.12007&rft_id=info%3Apmid%2F27634903&rft_id=info%3Apmid%2F27634903&rft.externalDocID=27634903